Cargando…

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the past decades, the em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrahennadi, Samitha, Sami, Amer, Manna, Mita, Pauls, Mehrnoosh, Ahmed, Shahid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161804/ https://www.ncbi.nlm.nih.gov/pubmed/34064867 http://dx.doi.org/10.3390/curroncol28030168

Ejemplares similares

Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience †
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions
por: Laface, Carmelo, et al.
Publicado: (2023)

Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
por: Ali, Sanji, et al.
Publicado: (2022)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
por: Pauls, Mehrnoosh, et al.
Publicado: (2022)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2021)

Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
por: Ovcaricek, Tanja, et al.
Publicado: (2019)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
por: Schwartzberg, Lee, et al.
Publicado: (2020)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
por: Lu, Ming, et al.
Publicado: (2010)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features
por: Benefield, Halei C, et al.
Publicado: (2020)

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
por: Matutino, Adriana, et al.
Publicado: (2018)

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
por: Torrisi, Rosalba, et al.
Publicado: (2022)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
por: Rossi, L, et al.
Publicado: (2015)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022)

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer
por: Lovejoy, Leann A., et al.
Publicado: (2023)

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
por: Al Mahmasani, Layal, et al.
Publicado: (2023)

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2018)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer
por: Pauls, Mehrnoosh, et al.
Publicado: (2022)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021)

Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Gong, Chang, et al.
Publicado: (2016)

Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor–Positive, HER2-Negative Breast Cancer
por: Bowles, Harmony J., et al.
Publicado: (2015)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
por: Fusco, Nicola, et al.
Publicado: (2021)

ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients
por: Pianetti, Stefania, et al.
Publicado: (2023)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_om46p6ftdt1topg80nn9rjqb9m